AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02831049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-extinction
Description: Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
Study NCT03435367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: VR with head mounted display (HMD) and headphones.
Study NCT03435367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad Tablet
Description: iPad with headphones
Study NCT02324790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Description: The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
Study NCT02831049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-extinction
Description: Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
Study NCT02831049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-related cues
Description: Alcohol related cues
Study NCT04533451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02831049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-related cues
Description: Alcohol related cues
Study NCT04533451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT04533451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04533451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Ancillary studies
Study NCT04310449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft and customized healing abutment
Description: Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
Study NCT04310449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual zone concept and customized healing abutment
Description: Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
Study NCT02490956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Verorab® (PVRV; Purified Vero Cell Vaccine)
Description: * Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363
Study NCT04533451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01527305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
Study NCT04161092 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver transplantation Ltx
Description: Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
Study NCT04161092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best alternative care
Description: All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
Study NCT02963571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior percutaneous pedicle screw internal fixation
Description: The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
Study NCT01267370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy polysaccharide fiber
Description: Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)
Study NCT01267370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy polysaccharide fiber
Description: Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)
Study NCT02831049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soft-drink related cues
Description: Soft drink related cues
Study NCT03581292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03581292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03581292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT01279720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of transduced cells
Description: Intravenous infusion of transduced cells
Study NCT03115216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FLA-CEIOL
Description: Femtosecond laser-assisted cataract extraction and intraocular lens placement
Study NCT03115216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEIOL
Description: Manual cataract extraction and intraocular lens placement
Study NCT04309890 — intervention group
Intervention type: OTHER
Intervention: Arabic version of the Overactive Bladder Symptom Score Questionnaire
Description: All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
Study NCT04268329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational website
Description: A website is used to educate patients and family members about head and neck cancer.
Study NCT03116828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
Study NCT03116828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
Study NCT00024024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Study NCT02547038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole+bismuth+tetra+metro
Description: pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
Study NCT02547038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (panto+amox+clar+metr)+(panto+amox)
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Study NCT00945347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miglustat
Description: Nasal instillation of miglustat
Study NCT00945347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal instillation of placebo matching in appearance with the Miglustat instillation
Study NCT04976673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
Study NCT04976673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
Study NCT00964665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albinterferon alfa-2b
Study NCT00964665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys®
Study NCT05345574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: dexmedetomidine as anaesthetic adjuvant
Study NCT05345574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil infusion
Description: remifentanil as anaesthetic adjuvant
Study NCT03278717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a PARP inhibitor, targeting DNA repair processes.
Study NCT03278717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a PARP inhibitor, targeting DNA repair processes.
Study NCT03278717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
Study NCT01681654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
Study NCT01681654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance Intervention
Description: Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
Study NCT03172871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
Study NCT03172871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
Study NCT03172871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole tablet
Description: Oral aripiprazole tablets 10 to 20 mg daily
Study NCT03172871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet
Description: Oral aripiprazole tablets 10 to 20 mg daily
Study NCT02549807 — intervention group
Intervention type: DEVICE
Intervention: Muscle elasticity measure
Description: an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
Study NCT03307603 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium-90 radioembolization
Description: Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
Study NCT03307603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib - nivolumab
Description: 240 mg intravenously
Study NCT03307603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II - nivolumab
Description: nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
Study NCT04270149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESR1 peptide vaccine
Description: ESR1 peptides plus Montanide and GM-CSF
Study NCT04115514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
Description: Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway.
Study NCT04115514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-intervention
Description: Standard of Care (SOC)
Study NCT04234204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral
Study NCT04234204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fezolinetant
Description: Oral
Study NCT04234204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01009944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril, Atenolol
Description: once a day for 14 weeks
Study NCT03106441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy by nasal cannula. Optiflow®
Description: Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
Study NCT03106441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask oxygenation in BIPAP ventilation
Description: Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
Study NCT03601039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absnow Absorbable ASD Closure System
Description: the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
Study NCT01293344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled nutritional intervention based on the Mediterranean diet
Description: Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
Study NCT01293344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled nutritional intervention based on the Mediterranean diet
Description: Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
Study NCT01940367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS (Percutaneous Tibial Nerve Stimulation
Description: PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
Study NCT01940367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Description: TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level
Study NCT01893411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (16 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
Study NCT01893411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (12 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
Study NCT01893411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (4 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
Study NCT03916536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium Laser
Description: Holmium laser enucleation of large sized prostate